KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Finished Goods (2016 - 2024)

Nektar Therapeutics has reported Finished Goods over the past 13 years, most recently at $2.2 million for Q2 2024.

  • Quarterly results put Finished Goods at $2.2 million for Q2 2024, changed N/A from a year ago — trailing twelve months through Jun 2024 was $2.2 million (changed N/A YoY), and the annual figure for FY2023 was $1.4 million, down 76.86%.
  • Finished Goods for Q2 2024 was $2.2 million at Nektar Therapeutics, down from $4.3 million in the prior quarter.
  • Over the last five years, Finished Goods for NKTR hit a ceiling of $5.9 million in Q4 2022 and a floor of $921000.0 in Q3 2023.
  • Median Finished Goods over the past 3 years was $2.2 million (2024), compared with a mean of $2.9 million.
  • Peak annual rise in Finished Goods hit 76.86% in 2023, while the deepest fall reached 76.86% in 2023.
  • Nektar Therapeutics' Finished Goods stood at $5.9 million in 2022, then plummeted by 76.86% to $1.4 million in 2023, then surged by 58.53% to $2.2 million in 2024.
  • The last three reported values for Finished Goods were $2.2 million (Q2 2024), $4.3 million (Q1 2024), and $1.4 million (Q4 2023) per Business Quant data.